Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (737)	10/12/1999 11:37:00 PM
From: Larry Liebman	Read Replies (1) \| Respond to of 4474

With the death spiral dead, $40 million in cash on the way, $11 million in the bank on 6/30, ARIA technology is effectively valued at $0. ARGENT + Phase 1 for GvHD + partnered/milestone achieving osteo program + signal transduction research dating < '95, i.e. NF-kB gene = $0. I think one of the most important effects of the cash infusion is the ability to bargain with big pharma. Until today, everyone knew the desperate ARIA cash/dilution situation. Pharma could adopt a wait and pick-up-the-pieces bias. Why buy now, when the fire sale was around the corner. Based on the news, ARIA now owns an extremely positive risk/reward profile. I'm curious as to Michael King's interpretation of the news.